

CITATION REPORT

List of articles citing

Monoamine oxidase B inhibitor, selegiline, reduces F-THK5351 uptake in the human brain

DOI: 10.1186/s13195-017-0253-y

Alzheimer's Research and Therapy, 2017, 9, 25.

Source: <https://exaly.com/paper-pdf/67596807/citation-report.pdf>

Version: 2024-04-28

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
249	Is Tau Imaging More Than Just Upside-Down F-FDG Imaging?. <i>Journal of Nuclear Medicine</i> , 2017 , 58, 1357-1359	8.8	14
248	F-flortaucipir tau positron emission tomography distinguishes established progressive supranuclear palsy from controls and Parkinson disease: A multicenter study. 2017 , 82, 622-634		106
247	Tau Diagnostics and Clinical Studies. 2017 , 63, 123-130		7
246	Characterization of the radiosynthesis and purification of [F]THK-5351, a PET ligand for neurofibrillary tau. 2017 , 130, 230-237		7
245	Multimodal correlation of dynamic [F]-AV-1451 perfusion PET and neuronal hypometabolism in [F]-FDG PET. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2017 , 44, 2249-2256	8.8	10
244	Molecular imaging in early diagnosis, differential diagnosis and follow-up of patients with neurodegenerative diseases. 2017 , 5, 465-471		6
243	New PET markers for the diagnosis of dementia. 2017 , 30, 608-616		10
242	Specific protein biomarker patterns for Alzheimer's disease: improved diagnostics in progress. 2017 , 8, 255-259		9
241	Small-molecule PET Tracers for Imaging Proteinopathies. 2017 , 47, 553-575		65
240	Regional tau deposition and subregion atrophy of medial temporal structures in early Alzheimer's disease: A combined positron emission tomography/magnetic resonance imaging study. 2017 , 9, 35-40		23
239	Tau positron emission tomography using [F]THK5351 and cerebral glucose hypometabolism in Alzheimer's disease. 2017 , 59, 210-219		35
238	Tau-imaging in neurodegeneration. 2017 , 130, 114-123		26
237	Potential Use of 18F-THK5351 PET to Identify Wallerian Degeneration of the Pyramidal Tract Caused by Cerebral Infarction. <i>Clinical Nuclear Medicine</i> , 2017 , 42, e523-e524	1.7	13
236	Quantitative positron emission tomography in brain research. 2017 , 1670, 220-234		27
235	[Development of SPECT Probes for In Vivo Imaging of β Amyloid and Tau Aggregates in the Alzheimer's Disease Brain]. 2017 , 137, 1361-1365		3
234	Tau Imaging for a Diagnostic Platform of Tauopathy Using the rTg4510 Mouse Line. 2017 , 8, 663		7
233	Comparative binding properties of the tau PET tracers THK5117, THK5351, PBB3, and T807 in postmortem Alzheimer brains. <i>Alzheimer's Research and Therapy</i> , 2017 , 9, 96	9	65

232	The emerging role of PET imaging in dementia. 2017 , 6, 1830		36
231	Targeting Alzheimer's Disease at the Right Time and the Right Place: Validation of a Personalized Approach to Diagnosis and Treatment. <i>Journal of Alzheimer's Disease</i> , 2018 , 64, S23-S31	4.3	8
230	Tau positron emission tomography imaging in tauopathies: The added hurdle of off-target binding. 2018 , 10, 232-236		60
229	Imaging tau and amyloid- β proteinopathies in Alzheimer disease and other conditions. 2018 , 14, 225-236		211
228	Comparative In Vitro and In Vivo Quantifications of Pathologic Tau Deposits and Their Association with Neurodegeneration in Tauopathy Mouse Models. <i>Journal of Nuclear Medicine</i> , 2018 , 59, 960-966	8.9	47
227	In vivo [F]-AV-1451 tau-PET imaging in sporadic Creutzfeldt-Jakob disease. 2018 , 90, e896-e906		20
226	[Biomarker-based diagnostics of Alzheimer's disease : Concept of suspected non-Alzheimer pathology]. 2018 , 89, 345-358		4
225	The tau positron-emission tomography tracer AV-1451 binds with similar affinities to tau fibrils and monoamine oxidases. <i>Movement Disorders</i> , 2018 , 33, 273-281	7	90
224	Tau Imaging in Parkinsonism: What Have We Learned So Far?. 2018 , 5, 118-130		9
223	Characterization of 3 Novel Tau Radiopharmaceuticals, C-RO-963, C-RO-643, and F-RO-948, in Healthy Controls and in Alzheimer Subjects. <i>Journal of Nuclear Medicine</i> , 2018 , 59, 1869-1876	8.9	61
222	Quantitative evaluation of tau PET tracers F-THK5351 and F-AV-1451 in Alzheimer's disease with standardized uptake value peak-alignment (SUVP) normalization. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2018 , 45, 1596-1604	8.8	8
221	Case of progressive supranuclear palsy detected by tau imaging with [F]THK-5351 before the appearance of characteristic clinical features. 2018 , 18, 501-502		3
220	F-AV-1451 in Parkinson's Disease with and without dementia and in Dementia with Lewy Bodies. 2018 , 8, 4717		40
219	Molecular imaging: What is right and what is an illusion?. 2018 , 10, 217-220		11
218	Preclinical Evaluation of F-RO6958948, C-RO6931643, and C-RO6924963 as Novel PET Radiotracers for Imaging Tau Aggregates in Alzheimer Disease. <i>Journal of Nuclear Medicine</i> , 2018 , 59, 675-681	8.9	49
217	[18F]-THK5351 PET Imaging in Patients With Semantic Variant Primary Progressive Aphasia. 2018 , 32, 62-69		24
216	Flortaucipir tau PET imaging in semantic variant primary progressive aphasia. 2018 , 89, 1024-1031		61
215	Selective Tau Imaging:. <i>Journal of Nuclear Medicine</i> , 2018 , 59, 175-176	8.9	14

214	Correlations of F-THK5351 PET with Postmortem Burden of Tau and Astrogliosis in Alzheimer Disease. <i>Journal of Nuclear Medicine</i> , 2018 , 59, 671-674	8.9	97
213	Head to head comparison of [F] AV-1451 and [F] THK5351 for tau imaging in Alzheimer's disease and frontotemporal dementia. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2018 , 45, 432-442	8.8	38
212	MAO-B Inhibitors Do Not Block In Vivo Flortaucipir([F]-AV-1451) Binding. 2018 , 20, 356-360		37
211	Evaluation of the Feasibility of Screening Tau Radiotracers Using an Amyloid Biomathematical Screening Methodology. 2018 , 2018, 6287913		
210	F-THK5351 PET Imaging in Nonfluent-Agrammatic Variant Primary Progressive Aphasia. 2018 , 17, 110-119		3
209	F-THK5351 PET Imaging in the Behavioral Variant of Frontotemporal Dementia. 2018 , 17, 163-173		3
208	Visualization of ischemic stroke-related changes on F-THK-5351 positron emission tomography. 2018 , 8, 62		8
207	Imaging and Molecular Mechanisms of Alzheimer's Disease: A Review. <i>International Journal of Molecular Sciences</i> , 2018 , 19,	6.3	25
206	The Role of Tau Imaging in Parkinsonian Disorders. 2018 , 18, 86		7
205	Involvement of the Precuneus/Posterior Cingulate Cortex Is Significant for the Development of Alzheimer's Disease: A PET (THK5351, PiB) and Resting fMRI Study. <i>Frontiers in Aging Neuroscience</i> , 2018 , 10, 304	5.3	38
204	Association of deposition of tau and amyloid- β proteins with structural connectivity changes in cognitively normal older adults and Alzheimer's disease spectrum patients. 2018 , 8, e01145		11
203	The Binding of BF-227-Like Benzoxazoles to Human β Synuclein and Amyloid β Peptide Fibrils. 2018 , 17, 1536012118796297		4
202	Imaging Protein Misfolding in the Brain Using β Sheet Ligands. <i>Frontiers in Neuroscience</i> , 2018 , 12, 585	5.1	21
201	Emerging PET Radiotracers and Targets for Imaging of Neuroinflammation in Neurodegenerative Diseases: Outlook Beyond TSPO. 2018 , 17, 1536012118792317		107
200	[F]THK-5351 PET imaging in early-stage semantic variant primary progressive aphasia: a report of two cases and a literature review. 2018 , 18, 109		12
199	Dual tracer tau PET imaging reveals different molecular targets for C-THK5351 and C-PBB3 in the Alzheimer brain. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2018 , 45, 1605-1617	8.8	27
198	The Place of PET to Assess New Therapeutic Effectiveness in Neurodegenerative Diseases. 2018 , 2018, 7043578		9
197	PET/CT of Dementia. 2018 , 211, 246-259		11

196	Single-word comprehension deficits in the nonfluent variant of primary progressive aphasia. <i>Alzheimer's Research and Therapy</i> , 2018 , 10, 68	9	10
195	In vivo quantification of neurofibrillary tangles with [F]MK-6240. <i>Alzheimer's Research and Therapy</i> , 2018 , 10, 74	9	69
194	Neuroimaging-pathological correlations of [F]THK5351 PET in progressive supranuclear palsy. 2018 , 6, 53		37
193	Dissociation of Tau Deposits and Brain Atrophy in Early Alzheimer's Disease: A Combined Positron Emission Tomography/Magnetic Resonance Imaging Study. <i>Frontiers in Aging Neuroscience</i> , 2018 , 10, 223	5.3	11
192	From simultaneous to synergistic MR-PET brain imaging: A review of hybrid MR-PET imaging methodologies. 2018 , 39, 5126-5144		41
191	Comparison of F-T807 and F-THK5117 PET in a Mouse Model of Tau Pathology. <i>Frontiers in Aging Neuroscience</i> , 2018 , 10, 174	5.3	13
190	Tau Filaments and the Development of Positron Emission Tomography Tracers. 2018 , 9, 70		21
189	Role of Neuroimaging as a Biomarker for Neurodegenerative Diseases. 2018 , 9, 265		20
188	Clinical Routine FDG-PET Imaging of Suspected Progressive Supranuclear Palsy and Corticobasal Degeneration: A Gatekeeper for Subsequent Tau-PET Imaging?. 2018 , 9, 483		14
187	Distinct [F]THK5351 binding patterns in primary progressive aphasia variants. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2018 , 45, 2342-2357	8.8	8
186	The development and validation of tau PET tracers: current status and future directions. 2018 , 6, 305-316		102
185	Large inter- and intra-case variability of first generation tau PET ligand binding in neurodegenerative dementias. 2018 , 6, 34		20
184	Progressive supranuclear palsy and multiple system atrophy: clinicopathological concepts and therapeutic challenges. 2018 , 31, 448-454		14
183	Evaluation of F-RO-948 PET for Quantitative Assessment of Tau Accumulation in the Human Brain. <i>Journal of Nuclear Medicine</i> , 2018 , 59, 1877-1884	8.9	44
182	S-[18F]THK-5117-PET and [11C]PIB-PET Imaging in Idiopathic Normal Pressure Hydrocephalus in Relation to Confirmed Amyloid-Plaques and Tau in Brain Biopsies. <i>Journal of Alzheimer's Disease</i> , 2018 , 64, 171-179	4.3	12
181	Brain Imaging of Alzheimer Dementia Patients and Elderly Controls with F-MK-6240, a PET Tracer Targeting Neurofibrillary Tangles. <i>Journal of Nuclear Medicine</i> , 2019 , 60, 107-114	8.9	63
180	In Vivo Characterization and Quantification of Neurofibrillary Tau PET Radioligand F-MK-6240 in Humans from Alzheimer Disease Dementia to Young Controls. <i>Journal of Nuclear Medicine</i> , 2019 , 60, 93-99	8.9	106
179	Differences in gray and white matter F-THK5351 uptake between behavioral-variant frontotemporal dementia and other dementias. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2019 , 46, 357-366	8.8	13

178	Identification of AV-1451 as a Weak, Nonselective Inhibitor of Monoamine Oxidase. <i>ACS Chemical Neuroscience</i> , 2019 , 10, 3839-3846	5.7	26
177	Topographical Heterogeneity of Alzheimer's Disease Based on MR Imaging, Tau PET, and Amyloid PET. <i>Frontiers in Aging Neuroscience</i> , 2019 , 11, 211	5.3	14
176	[F]GTP1 (Genentech Tau Probe 1), a radioligand for detecting neurofibrillary tangle tau pathology in Alzheimer's disease. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2019 , 46, 2077-2089 ^{8.8}	8.8	50
175	Applications of Neuroimaging Biomarkers in CNS Drug Development. 2019 , 115-158		
174	Discovery and preclinical characterization of [F]PI-2620, a next-generation tau PET tracer for the assessment of tau pathology in Alzheimer's disease and other tauopathies. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2019 , 46, 2178-2189	8.8	88
173	THK5351 and flortaucipir PET with pathological correlation in a Creutzfeldt-Jakob disease patient: a case report. 2019 , 19, 211		5
172	AD molecular: Imaging tau aggregates with positron emissions tomography. 2019 , 165, 107-138		7
171	Neuroimaging of Alzheimer's disease: focus on amyloid and tau PET. 2019 , 37, 735-749		29
170	PET-detectable tau pathology correlates with long-term neuropsychiatric outcomes in patients with traumatic brain injury. 2019 , 142, 3265-3279		31
169	PET Imaging of Astrogliosis and Tau Facilitates Diagnosis of Parkinsonian Syndromes. <i>Frontiers in Aging Neuroscience</i> , 2019 , 11, 249	5.3	16
168	Optimal timing of tau pathology imaging and automatic extraction of a reference region using dynamic [F]THK5317 PET. 2019 , 22, 101681		2
167	Tau PET With F-THK-5351 Taiwan Patients With Familial Alzheimer's Disease With the APP p.D678H Mutation. 2019 , 10, 503		6
166	A new perspective for advanced positron emission tomography-based molecular imaging in neurodegenerative proteinopathies. 2019 , 15, 1081-1103		10
165	Four-repeat tauopathies. 2019 , 180, 101644		77
164	Tau Imaging in Neurodegenerative Diseases Using Positron Emission Tomography. 2019 , 19, 45		34
163	F-Flortaucipir in TDP-43 associated frontotemporal dementia. 2019 , 9, 6082		18
162	Longitudinal changes in F-THK5351 positron emission tomography in corticobasal syndrome. 2019 , 26, 1205-1211		9
161	The elusive tau molecular structures: can we translate the recent breakthroughs into new targets for intervention?. 2019 , 7, 31		35

160	Cross-interaction of tau PET tracers with monoamine oxidase B: evidence from in silico modelling and in vivo imaging. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2019 , 46, 1369-1382	8.8	45
159	Autoradiography validation of novel tau PET tracer [F-18]-MK-6240 on human postmortem brain tissue. 2019 , 7, 37		63
158	Characterization of the binding of tau imaging ligands to melanin-containing cells: putative off-target-binding site. <i>Annals of Nuclear Medicine</i> , 2019 , 33, 375-382	2.5	12
157	A walk through tau therapeutic strategies. 2019 , 7, 22		133
156	Discovery of N-(4-[F]Fluoro-5-methylpyridin-2-yl)isoquinolin-6-amine (JNJ-64326067), a New Promising Tau Positron Emission Tomography Imaging Tracer. 2019 , 62, 2974-2987		14
155	Clinical heterogeneity of frontotemporal dementia and Parkinsonism linked to chromosome 17 caused by MAPT N279K mutation in relation to tau positron emission tomography features. <i>Movement Disorders</i> , 2019 , 34, 568-574	7	10
154	Rasagiline, a monoamine oxidase B inhibitor, reduces in vivo [F]THK5351 uptake in progressive supranuclear palsy. 2019 , 24, 102091		12
153	Update on PET in neurodegenerative and neuroinflammatory disorders manifesting on a behavioural level: imaging for differential diagnosis. 2019 , 32, 548-556		4
152	Current and emerging therapeutic targets of alzheimer's disease for the design of multi-target directed ligands. 2019 , 10, 2052-2072		30
151	Monoamine Oxidase B Binding of 18F-THK5351 to Visualize Glioblastoma and Associated Gliosis: An Autopsy-Confirmed Case. <i>Clinical Nuclear Medicine</i> , 2019 , 44, 507-509	1.7	8
150	In Vivo Assessment of Tau Deposition in Alzheimer Disease and Assessing Its Relationship to Regional Brain Glucose Metabolism and Cognition. <i>Clinical Nuclear Medicine</i> , 2019 , 44, e597-e601	1.7	14
149	Intra-individual correlations between quantitative THK-5351 PET and MRI-derived cortical volume in Alzheimer's disease differ according to disease severity and amyloid positivity. 2019 , 14, e0226265		5
148	Comparison of Amyloid and Tau Spread Models in Alzheimer's Disease. 2019 , 29, 4291-4302		10
147	A simplified radiosynthesis of [F]MK-6240 for tau PET imaging. 2019 , 62, 109-114		7
146	Longitudinal tau and metabolic PET imaging in relation to novel CSF tau measures in Alzheimer's disease. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2019 , 46, 1152-1163	8.8	23
145	Data-driven approaches for tau-PET imaging biomarkers in Alzheimer's disease. 2019 , 40, 638-651		17
144	Biomarkers for tau pathology. 2019 , 97, 18-33		96
143	Tau imaging detects distinctive distribution of tau pathology in ALS/PDC on the Kii Peninsula. 2019 , 92, e136-e147		11

142	PET imaging of tau protein targets: a methodology perspective. 2019 , 13, 333-344		31
141	Preclinical Safety Evaluation and Human Dosimetry of [F]MK-6240, a Novel PET Tracer for Imaging Neurofibrillary Tangles. 2020 , 22, 173-180		11
140	Advances in CNS PET: the state-of-the-art for new imaging targets for pathophysiology and drug development. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2020 , 47, 451-489	8.8	50
139	Structure-Activity Relationships of Radioiodinated 6,5,6-Tricyclic Compounds for the Development of Tau Imaging Probes. 2020 , 11, 120-126		3
138	Evaluation of [F]-Methyl lansoprazole as a Tau PET Imaging Agent in First-in-Human Studies. <i>ACS Chemical Neuroscience</i> , 2020 , 11, 427-435	5.7	13
137	Binding of [F]AV1451 in post mortem brain slices of semantic variant primary progressive aphasia patients. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2020 , 47, 1949-1960	8.8	6
136	Tau PET imaging with F-PI-2620 in Patients with Alzheimer Disease and Healthy Controls: A First-in-Humans Study. <i>Journal of Nuclear Medicine</i> , 2020 , 61, 911-919	8.9	63
135	Tau Tangles in Parkinson's Disease: A 2-Year Follow-Up Flortaucipir PET Study. 2020 , 10, 161-171		3
134	18F-THK5351 PET Can Identify Astrogliosis in Multiple Sclerosis Plaques. <i>Clinical Nuclear Medicine</i> , 2020 , 45, e98-e100	1.7	10
133	The Imaging Features and Clinical Associations of a Novel Tau PET Tracer-18F-APN1607 in Alzheimer Disease. <i>Clinical Nuclear Medicine</i> , 2020 , 45, 747-756	1.7	11
132	Clinical Evaluation of 18F-PI-2620 as a Potent PET Radiotracer Imaging Tau Protein in Alzheimer Disease and Other Neurodegenerative Diseases Compared With 18F-THK-5351. <i>Clinical Nuclear Medicine</i> , 2020 , 45, 841-847	1.7	9
131	Investigation of reactive astrogliosis effect on post-stroke cognitive impairment. 2020 , 17, 308		3
130	18F-MK-6240 PET for early and late detection of neurofibrillary tangles. 2020 , 143, 2818-2830		65
129	Relationship between the temporal course of astrogliosis and symptom improvement in cerebral infarction: report of a case monitored using F-THK5351 positron emission tomography. 2020 , 20, 81		3
128	Discovery of 2-(4-(2-fluoroethoxy)piperidin-1-yl)-9-methyl-9H-pyrrolo[2,3-b:4,5-c']dipyridine ([18F]PI-2014) as PET tracer for the detection of pathological aggregated tau in Alzheimer's disease and other tauopathies. 2020 , 204, 112615		4
127	Amyloid and Tau PET Imaging of Alzheimer Disease and Other Neurodegenerative Conditions. 2020 , 41, 572-583		6
126	Association between neurite metrics and tau/inflammatory pathology in Alzheimer's disease. 2020 , 12, e12125		4
125	F-THK5351 PET imaging in patients with progressive supranuclear palsy: associations with core domains and diagnostic certainty. 2020 , 10, 19410		6

124	Novel PET Biomarkers to Disentangle Molecular Pathways across Age-Related Neurodegenerative Diseases. 2020 , 9,		12
123	Neuroimaging Advances in Parkinson's Disease and Atypical Parkinsonian Syndromes. 2020 , 11, 572976		16
122	Association of Subcortical Structural Shapes With Tau, Amyloid, and Cortical Atrophy in Early-Onset and Late-Onset Alzheimer's Disease. <i>Frontiers in Aging Neuroscience</i> , 2020 , 12, 563559	5.3	4
121	Clinical evaluation of [¹⁸ F] JNJ-64326067, a novel candidate PET tracer for the detection of tau pathology in Alzheimer's disease. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2020 , 47, 3176-3185	8.8	10
120	Associations of [¹⁸ F]-APN-1607 Tau PET Binding in the Brain of Alzheimer's Disease Patients With Cognition and Glucose Metabolism. <i>Frontiers in Neuroscience</i> , 2020 , 14, 604	5.1	9
119	[¹⁸ F]THK5317 imaging as a tool for predicting prospective cognitive decline in Alzheimer's disease. 2020 ,		8
118	PET and SPECT imaging of the brain: a review on the current status of nuclear medicine in Japan. 2020 , 38, 343-357		6
117	Early-phase [¹⁸ F]PI-2620 tau-PET imaging as a surrogate marker of neuronal injury. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2020 , 47, 2911-2922	8.8	24
116	Biomarkers for Alzheimer's disease-preparing for a new era of disease-modifying therapies. 2021 , 26, 296-308		85
115	One-Stop Shop: F-Flortaucipir PET Differentiates Amyloid-Positive and -Negative Forms of Neurodegenerative Diseases. <i>Journal of Nuclear Medicine</i> , 2021 , 62, 240-246	8.9	6
114	A critical review of radiotracers in the positron emission tomography imaging of traumatic brain injury: FDG, tau, and amyloid imaging in mild traumatic brain injury and chronic traumatic encephalopathy. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2021 , 48, 623-641	8.8	11
113	Radiosynthesis and quality control testing of the tau imaging positron emission tomography tracer [¹⁸ F]PM-PBB3 for clinical applications. 2021 , 64, 109-119		4
112	Synthesis and evaluation of 2-pyrrolopyridinylquinoline derivatives as selective tau PET tracers for the diagnosis of Alzheimer's disease. 2021 , 93, 11-18		3
111	An evaluation of the amyloid cascade model using in vivo positron emission tomographic imaging. 2021 , 21, 14-23		1
110	Imaging of Tau Pathology in Neurodegenerative Diseases: An Update. 2021 , 51, 253-263		10
109	High-Contrast In Vivo Imaging of Tau Pathologies in Alzheimer's and Non-Alzheimer's Disease Tauopathies. 2021 , 109, 42-58.e8		53
108	Development and evaluation of [¹⁸ F]IPPI for Tau imaging in postmortem human Alzheimer's disease brain. 2021 , 75, e22183		2
107	Analysis of amyloid and tau deposition in Alzheimer's disease using C-Pittsburgh compound B and F-THK 5351 positron emission tomography imaging. 2021 , 20, 61-72		1

106	Synthesis and Evaluation of Fluorine-18 Labeled 2-Phenylquinoxaline Derivatives as Potential Tau Imaging Agents. 2021 , 18, 1176-1195		4
105	Positron emission tomography imaging agents for evaluating the pathologic features of Alzheimer's disease and drug development. 2021 , 367-412		
104	PET and SPECT Imaging of Neurodegenerative Diseases. 2021 , 1309-1334		
103	Radioactive synthesis of tau PET imaging agent F-AV-1451 and its role in monitoring the progression of Alzheimer's disease and supporting differential diagnosis. <i>Annals of Nuclear Medicine</i> , 2021 , 35, 139-147	2.5	1
102	Effects of Alzheimer's and Vascular Pathologies on Structural Connectivity in Early- and Late-Onset Alzheimer's Disease. <i>Frontiers in Neuroscience</i> , 2021 , 15, 606600	5.1	0
101	Centiloid scale analysis for F-THK5351 PET imaging in Alzheimer's disease. 2021 , 82, 249-254		2
100	Gray matter structural networks related to F-THK5351 retention in cognitively normal older adults and Alzheimer's disease patients. 2021 , 22, 100309		3
99	F-THK-5351, Fluorodeoxyglucose, and Florbetaben PET Images in Atypical Alzheimer's Disease: A Pictorial Insight into Disease Pathophysiology. 2021 , 11,		1
98	Neuroinflammation is highest in areas of disease progression in semantic dementia. 2021 , 144, 1565-1575		7
97	Molecular Imaging of Extrapyraxidal Movement Disorders With Dementia: The 4R Tauopathies. 2021 , 51, 275-285		2
96	Combination of automated brain volumetry on MRI and quantitative tau deposition on THK-5351 PET to support diagnosis of Alzheimer's disease. 2021 , 11, 10343		3
95	Cortical [F]PI-2620 Binding Differentiates Corticobasal Syndrome Subtypes. <i>Movement Disorders</i> , 2021 , 36, 2104-2115	7	6
94	Binding characteristics of [F]PI-2620 distinguish the clinically predicted tau isoform in different tauopathies by PET. 2021 , 271678X211018904		9
93	PET Agents in Dementia: An Overview. 2021 , 51, 196-229		10
92	PET Neuroimaging of Alzheimer's Disease: Radiotracers and Their Utility in Clinical Research. <i>Frontiers in Aging Neuroscience</i> , 2021 , 13, 624330	5.3	5
91	Clinical Utility of F-APN-1607 Tau PET Imaging in Patients with Progressive Supranuclear Palsy. <i>Movement Disorders</i> , 2021 , 36, 2314-2323	7	4
90	Voxel-based correlation of F-THK5351 accumulation with gray matter structural networks in cognitively normal older adults. 2021 , 23, 100343		
89	18F-THK5351 PET Can Identify Core Lesions in Different Amyotrophic Lateral Sclerosis Phenotypes. <i>Clinical Nuclear Medicine</i> , 2021 , 46, e582-e583	1.7	2

88	Thiophene-Based Optical Ligands That Selectively Detect A β Pathology in Alzheimer's Disease. 2021 , 22, 2568-2581		1
87	Recurrent Lobar Hemorrhages and Multiple Cortical Superficial Siderosis in a Patient of Alzheimer's Disease With Homozygous APOE ϵ Allele Presenting Hypobetalipoproteinemia and Pathological Findings of F-THK5351 Positron Emission Tomography: A Case Report. 2021 , 12, 645625		
86	Superiority of Formalin-Fixed Paraffin-Embedded Brain Tissue for Assessment of Progressive Supranuclear Palsy Tau Pathology With [F]PI-2620. 2021 , 12, 684523		1
85	Evolving concepts in progressive supranuclear palsy and other 4-repeat tauopathies. 2021 , 17, 601-620		5
84	(S)-[F]THK5117 brain uptake is associated with A β plaques and MAO-B enzyme in a mouse model of Alzheimer's disease. 2021 , 196, 108676		2
83	Positron emission tomography in multiple sclerosis - straight to the target. 2021 , 17, 663-675		2
82	Artificial Intelligence and the Future of Diagnostic and Therapeutic Radiopharmaceutical Development:: In Silico Smart Molecular Design. 2021 , 16, 513-523		3
81	Tau aggregation and increased neuroinflammation in athletes after sports-related concussions and in traumatic brain injury patients - A PET/MR study. 2021 , 30, 102665		5
80	PET Chemistry: Radiopharmaceuticals. 2021 , 177-199		
79	Identification of Heterogeneous Subtypes of Mild Cognitive Impairment Using Cluster Analyses Based on PET Imaging of Tau and Astrogliosis. <i>Frontiers in Aging Neuroscience</i> , 2020 , 12, 615467	5-3	4
78	PET Neuroimaging in Dementia Conditions. 2021 , 211-282		2
77	Tau Accumulation and Network Breakdown in Alzheimer's Disease. 2019 , 1184, 231-240		3
76	Neuroimaging in Dementia. 2017 , 37, 510-537		34
75	New advances in tau imaging in parkinsonism. 2017 , 29, 628-635		4
74	18F-THK5351 PET Can Identify Lesions of Acute Traumatic Brain Injury. <i>Clinical Nuclear Medicine</i> , 2020 , 45, e491-e492	1-7	3
73	Head-to-Head Comparison of the Two MAO-B Radioligands, 18F-THK5351 and 11C-L-Deprenyl, to Visualize Astrogliosis in Patients With Neurological Disorders. <i>Clinical Nuclear Medicine</i> , 2021 , 46, e31-e33 ¹⁷		5
72	Frontal Variant of Alzheimer Disease Differentiated From Frontotemporal Dementia Using in Vivo Amyloid and Tau Imaging. 2020 , 33, 288-293		3
71	High-contrast in-vivo imaging of tau pathologies in Alzheimer's and non-Alzheimer's disease tauopathies.		6

70	In vivo characterization and quantification of neurofibrillary tau PET radioligand [18F]MK-6240 in humans from Alzheimer's disease dementia to young controls.		3
69	Voxel-based correlation of F-THK5351 accumulation and gray matter volume in the brain of cognitively normal older adults. 2019 , 9, 81		3
68	Comparison of regional flortaucipir PET with quantitative tau immunohistochemistry in three subjects with Alzheimer's disease pathology: a clinicopathological study. 2020 , 10, 65		13
67	Tau Positron Emission Tomography Imaging in Degenerative Parkinsonisms. 2018 , 11, 1-12		5
66	What Is T+? A Gordian Knot of Tracers, Thresholds, and Topographies. <i>Journal of Nuclear Medicine</i> , 2021 , 62, 614-619	8.9	5
65	Pick's Tau Fibril Shows Multiple Distinct PET Probe Binding Sites: Insights from Computational Modelling. <i>International Journal of Molecular Sciences</i> , 2020 , 22,	6.3	2
64	Relationships between [18F]-THK5351 Retention and Language Functions in Primary Progressive Aphasia. <i>Journal of Clinical Neurology (Korea)</i> , 2019 , 15, 527-536	1.7	2
63	[18F]THK5351 PET Imaging in Patients with Mild Cognitive Impairment. <i>Journal of Clinical Neurology (Korea)</i> , 2020 , 16, 202-214	1.7	4
62	18F-MK-6240 tau-PET in genetic frontotemporal dementia. 2021 ,		1
61	Characterization of an APP/tau rat model of Alzheimer's disease by positron emission tomography and immunofluorescent labeling. <i>Alzheimer's Research and Therapy</i> , 2021 , 13, 175	9	2
60	Longitudinal Assessment of Tau-Associated Pathology by F-THK5351 PET Imaging: A Histological, Biochemical, and Behavioral Study. 2021 , 11,		1
59	Clinical Meaningfulness of Biomarker Endpoints in Alzheimer's Disease Research. 2018 , 235-248		
58	Data-driven approaches for Tau-PET imaging biomarkers in Alzheimer's disease.		1
57	First in-human PET study of 3 novel tau radiopharmaceuticals: [11C]RO6924963, [11C]RO6931643, and [18F]RO6958948.		1
56	Visualization of Motor Cortex Involvement by 18F-THK5351 PET Potentially Strengthens Diagnosis of Amyotrophic Lateral Sclerosis. <i>Clinical Nuclear Medicine</i> , 2021 , 46, 243-245	1.7	6
55	Amyloid and Tau in Alzheimer's Disease: Biomarkers or Molecular Targets for Therapy? Are We Shooting the Messenger?. 2021 , 178, 1014-1025		1
54	In vivo visualization of propagating β -synuclein pathologies in mouse and marmoset models by a bimodal imaging probe, C05-05.		2
53	F-THK 5351 and C-PiB PET of the Thai normal brain template. 2021 , 9, 21-30		

52	Neuronal PET tracers for Alzheimer's disease. 2021 , 587, 58-62		1
51	Tau Imaging in Neurodegenerative Dementia. 2022 , 111-120		
50	Progressive Supranuclear Palsy. 2022 , 347-359		
49	F-THK5351 Positron Emission Tomography Imaging in Neurodegenerative Tauopathies.. <i>Frontiers in Aging Neuroscience</i> , 2021 , 13, 761010	5.3	4
48	Patterns of Distribution of 18F-THK5351 Positron Emission Tomography in Alzheimer's Disease Continuum. <i>Journal of Alzheimer's Disease</i> , 2021 ,	4.3	1
47	Tau Biomarkers in Dementia: Positron Emission Tomography Radiopharmaceuticals in Tauopathy Assessment and Future Perspective. <i>International Journal of Molecular Sciences</i> , 2021 , 22,	6.3	0
46	Positron Emission Tomography in Animal Models of Tauopathies.. <i>Frontiers in Aging Neuroscience</i> , 2021 , 13, 761913	5.3	3
45	The Role of Chirality of [F]SMBT-1 in Imaging of Monoamine Oxidase-B.. <i>ACS Chemical Neuroscience</i> , 2022 ,	5.7	2
44	First-in-human evaluation of F-SMBT-1, a novel F-labeled MAO-B PET tracer for imaging reactive astrogliosis.. <i>Journal of Nuclear Medicine</i> , 2022 ,	8.9	5
43	Neuroimaging with PET/CT in chronic traumatic encephalopathy: what nuclear medicine can do to move the field forward.. <i>Expert Review of Molecular Diagnostics</i> , 2022 ,	3.8	1
42	Imaging of Reactive Astrogliosis by Positron Emission Tomography.. <i>Frontiers in Neuroscience</i> , 2022 , 16, 807435	5.1	4
41	Temporal and spatial changes in reactive astrogliosis examined by F-THK5351 positron emission tomography in a patient with severe traumatic brain injury.. <i>European Journal of Hybrid Imaging</i> , 2021 , 5, 26	1.7	0
40	F-THK5351 PET Positivity and Longitudinal Changes in Cognitive Function in β Amyloid-Negative Amnesic Mild Cognitive Impairment.. <i>Yonsei Medical Journal</i> , 2022 , 63, 259-264	3	0
39	Tau Imaging with 18F-MK6240 across the Alzheimer's Disease spectrum.		1
38	Recent development in selective Tau tracers for PET imaging in the brain. <i>Chinese Chemical Letters</i> , 2022 ,	8.1	0
37	F-THK5351 PET for visualizing predominant lesions of pathologically confirmed corticobasal degeneration presenting with frontal behavioral-spatial syndrome.. <i>Journal of Neurology</i> , 2022 , 1	5.5	
36	Data_Sheet_1.DOCX. 2018 ,		
35	Image_1.TIFF. 2018 ,		

34	Table_1.DOCX. 2018 ,		
33	Data_Sheet_1.doc. 2019 ,		
32	Image_1.tif. 2019 ,		
31	The tauopathies: Neuroimaging characteristics and emerging experimental therapies.. <i>Journal of Neuroimaging</i> , 2022 ,	2.8	
30	PET Imaging of Amyloid and Tau in Alzheimer's Disease. 2022 , 307-323		0
29	Amyloid and Tau Positron Emission Tomography Imaging in Alzheimer's Disease and Other Tauopathies.. <i>Frontiers in Aging Neuroscience</i> , 2022 , 14, 838034	5.3	4
28	PET Imaging in Preclinical Anti-A β Drug Development.. <i>Pharmaceutical Research</i> , 2022 , 1	4.5	0
27	PET-based classification of corticobasal syndrome.. <i>Parkinsonism and Related Disorders</i> , 2022 , 98, 92-98	3.6	0
26	MicroPET Imaging Assessment of Brain Tau and Amyloid Deposition in 6 μ g Alzheimer's Disease Model Mice. <i>International Journal of Molecular Sciences</i> , 2022 , 23, 5485	6.3	
25	PET Imaging in Animal Models of Alzheimer's Disease. <i>Frontiers in Neuroscience</i> , 2022 , 16,	5.1	
24	Monoamine oxidase binding not expected to significantly affect [18F]flortaucipir PET interpretation. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> ,	8.8	1
23	Long-term sequelae of mild-repetitive and severe traumatic brain injury: Clinical manifestations, neuropathology and diagnosis by tau PET imaging. 2022 , 123-135		
22	Safety and Efficacy of Semorinemab in Individuals With Prodromal to Mild Alzheimer Disease. <i>JAMA Neurology</i> ,	17.2	5
21	[18F]THK-5351 PET Patterns in Patients With Alzheimer's Disease and Negative Amyloid PET Findings. <i>Journal of Clinical Neurology (Korea)</i> , 2022 , 18, 437	1.7	0
20	Distribution Pattern of the Monoamine Oxidase B Ligand, 18F-THK5351, in the Healthy Brain. <i>Clinical Nuclear Medicine</i> , 2022 , 47, e489-e495	1.7	0
19	Age-related increase of monoamine oxidase B in amyloid-negative cognitively unimpaired elderly subjects. <i>Annals of Nuclear Medicine</i> ,	2.5	
18	Middle Cerebellar Peduncle in Early Stage of Multiple System Atrophy: A THK5351 PET Study. <i>Movement Disorders</i> ,	7	
17	In vivo imaging of tau deposition in Alzheimer's disease using both [18F]-THK5317 and [18F]-S16: A pilot human study. 14,		1

16	18F-THK5351 positron emission tomography imaging for Gerstmann-Strüssler-Scheinker disease. 2022 , 441, 120379	
15	From pathology to MRI and back: Clinically relevant biomarkers of multiple sclerosis lesions. 2022 , 36, 103194	1
14	Molecular Imaging in Parkinsonian Disorders—What’s New and Hot?. 2022 , 12, 1146	2
13	Free water derived by multi-shell diffusion MRI reflects tau/neuroinflammatory pathology in Alzheimer’s disease. 2022 , 8,	0
12	Brain PET Imaging of 11C-Methionine, 18F-FDG, and 18F-THK5351 in a Case of Lymphomatoid Granulomatosis. 2022 , 47, e749-e751	0
11	PET molecular imaging for pathophysiological visualization in Alzheimer’s disease.	1
10	Tau-PET Bildgebung der Demenzerkrankungen. 2022 , 45, 266-272	0
9	Tau-PET Bildgebung der Bewegungsstörungen. 2022 , 45, 273-277	0
8	Khellin as a selective monoamine oxidase B inhibitor ameliorated paclitaxel-induced peripheral neuropathy in mice. 2023 , 154673	0
7	The Monoamine Oxidase-B Inhibitor Selegiline Does Not Affect 18 F-Florzolotau Uptake in Patients with Progressive Supranuclear Palsy: A Longitudinal Case Series.	0
6	The hippocampus associated GABAergic neural network impairment in early-stage of Alzheimer’s disease. 2023 , 86, 101865	0
5	The Sensitivity of Tau Tracers for the Discrimination of Alzheimer’s Disease Patients and Healthy Controls by PET. 2023 , 13, 290	1
4	Evaluation of advanced, pathophysiologic new targets for imaging of CNS.	0
3	Thiophene-based Ligands: Design, Synthesis and Their Utilization for Optical Assignment of Polymorphic Disease Associated Protein Aggregates.	0
2	Towards standardization of tau PET imaging corresponding to various tau PET tracer: multi-center phantom study.	0
1	Tau-PET imaging in Parkinson’s disease: a systematic review and meta-analysis. 14,	0